Setpoint Medical raises $60M Series D for vagus nerve stimulation following landmark Nature publication
Summary
Setpoint Medical raised $60M in Series D funding from GSR Ventures, Euclidean Capital, and National Resilience, following the Nature publication of their pivotal RA trial. The round supports the pre-commercialization buildout ahead of FDA PMA submission for their implantable vagus nerve stimulator. Setpoint is pursuing FDA approval in rheumatoid arthritis as the primary indication with plans to expand to Crohn's disease and other inflammatory conditions.
Why it matters
Nature publication of pivotal trial data combined with a $60M Series D creates the strongest possible commercial launch foundation for a bioelectronic medicine company. Setpoint's path to FDA approval is now the clearest in bioelectronic medicine, and the RA indication opens a $25B+ market currently dominated by expensive biologics.
Want the full NeurotechMag Pro intelligence database?
Access 800+ papers, trials, patents, funding rounds and news items — updated daily.
Start free trial